Dual Targeting of Brain Tumor Initiating Cells through Inhibition of BMI1 and EZH2 (R01NS103434)
通过抑制 BMI1 和 EZH2 双重靶向脑肿瘤起始细胞 (R01NS103434)
基本信息
- 批准号:10201765
- 负责人:
- 金额:$ 34.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-30 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:AnatomyB-Cell LymphomasBMI1 geneBiopsyBlood VesselsBrain GlioblastomaBrain NeoplasmsBrain StemCell LineageCellsChromatinChromatin Remodeling FactorClassification SchemeClinical TrialsComplexCuesDataDependenceDevelopmentDoseEnhancersEnzymesEpigenetic ProcessGene Expression ProfileGene Expression ProfilingGeneticGenetic TranscriptionGlioblastomaGrowthHistologicHistone-Lysine N-MethyltransferaseHistonesHomologous GeneHumanHypoxiaInvadedLinkLocationLysineMalignant NeoplasmsMalignant neoplasm of brainMeasuresMediatingMesenchymalMesenchymal Cell NeoplasmMessenger RNAModelingMolecularNeoplasms in Vascular TissueNormal tissue morphologyOrganPRC1 ProteinPathway interactionsPatient SelectionPatientsPatternPharmaceutical PreparationsPharmacologyPolycombPopulationPrimary Brain NeoplasmsProteinsRadiationRadiation therapyRegimenRegulationResistanceResourcesRing Finger DomainSpecimenStressTherapeuticToxic effectTranscriptional ActivationTranslatingTumor AngiogenesisTumor Stem Cellsangiogenesisbasecancer cellclinical developmentclinically relevantconventional therapyepigenetic regulationimprovedin siliconeoplastic cellnovelpersonalized medicineprogramsprotein expressionresponseself-renewalstemstem cellstargeted treatmenttemozolomidetherapy resistanttumortumor heterogeneitytumor hypoxiatumor microenvironmentubiquitin-protein ligase
项目摘要
The most prevalent primary brain tumor, glioblastoma (GBM), ranks among the most lethal of human
cancers. Like the normal brain, GBMs contain cellular hierarchies with self-renewing, multi-lineage cells at
the apex. These brain tumor initiating cells (BTICs), or GBM stem cells, display therapeutic resistance,
promote tumor angiogenesis, and invade into normal tissues. BTICs are not uniformly distributed, but
rather concentrated in specific regions, or niches, including around blood vessels (the perivascular niche)
and in perinecrotic (hypoxic) regions. These niches provide essential cues that maintain stem-like tumor
cells through several pathways that appear specific for each location. In preliminary studies, we find that
biopsies of specific GBM regions contain tumor cells with divergent transcriptional profiles and precursor
markers. Cellular differentiation states reflect the cumulative regulation of chromatin, so we examined the
expression and activity of two core epigenetic regulatory nodes: polycomb repressive complexes 1 and 2
(PRC1/2). Vascular tumor regions were associated with PRC2 activity, whereas hypoxic regions were
associated with measures of PRC1. Collectively, these results suggest that stem-like cancer cells residing
in different locations may be regulated by different epigenetic programs.
Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase enzyme that serves as the
enzymatic component of PRC2. B lymphoma Mo-MLV insertion region 1 homolog (BMI1) is an essential
component of PRC1. Both EZH2 and BMI1 have been linked to normal and neoplastic stem cells, as well
as therapeutic resistance. Clinical relevance for BMI1 and EZH2 is supported by the development of
targeted therapies against each molecule. We find that mesenchymal BTICs display preferential activity
and dependence on BMI1, whereas proneural BTICs display preferential activity and dependence on
EZH2. As GBMs contain a mixture of proneural and mesenchymal tumor cells, we hypothesized that
combined targeting of BMI1 and EZH2 will offer improved tumor control with acceptable toxicity. Further,
we have identified a novel molecular regulatory mechanism of BMI1 linked to the hypoxic
microenvironment that may inform patient selection for precision (personalized) medicine application of
epigenetic targeting. Finally, additional studies will determine the potential of this therapeutic regimen to
synergize with conventional therapies against glioblastoma. Collectively, these studies will investigate novel
molecular regulation by the tumor microenvironment of neoplastic stem cells that can be directly translated
into clinical trials.
最常见的原发性脑肿瘤,胶质母细胞瘤(GBM),是人类最致命的肿瘤之一
癌症。与正常大脑一样,GBM 包含细胞层次结构,其中具有自我更新的多谱系细胞
顶点。这些脑肿瘤起始细胞 (BTIC) 或 GBM 干细胞表现出治疗耐药性,
促进肿瘤血管生成,并侵入正常组织。 BTIC 并不是均匀分布的,但是
相当集中在特定区域或生态位,包括血管周围(血管周围生态位)
以及坏死周围(缺氧)区域。这些生态位提供了维持干细胞样肿瘤的重要线索
细胞通过多个针对每个位置的特定途径。在初步研究中,我们发现
特定 GBM 区域的活检包含具有不同转录谱和前体的肿瘤细胞
标记。细胞分化状态反映了染色质的累积调节,因此我们检查了
两个核心表观遗传调控节点的表达和活性:多梳抑制复合物 1 和 2
(PRC1/2)。血管肿瘤区域与 PRC2 活性相关,而缺氧区域则与 PRC2 活性相关。
与 PRC1 的措施相关。总的来说,这些结果表明干细胞样癌细胞存在于
不同位置的基因可能受到不同表观遗传程序的调节。
zeste 同源物 2 (EZH2) 的增强子是一种组蛋白赖氨酸 N-甲基转移酶,充当
PRC2 的酶成分。 B 淋巴瘤 Mo-MLV 插入区 1 同源物 (BMI1) 是必需的
PRC1 的组成部分。 EZH2 和 BMI1 都与正常和肿瘤干细胞相关
作为治疗抵抗。 BMI1 和 EZH2 的临床相关性得到以下发展的支持
针对每个分子的靶向治疗。我们发现间充质 BTIC 显示出优先活性
和对 BMI1 的依赖性,而原神经 BTIC 显示出优先活性和对 BMI1 的依赖性
EZH2。由于 GBM 含有原神经和间充质肿瘤细胞的混合物,我们假设
BMI1 和 EZH2 的联合靶向将改善肿瘤控制并具有可接受的毒性。更远,
我们已经确定了 BMI1 与缺氧相关的新分子调节机制
微环境可以帮助患者选择精准(个性化)药物应用
表观遗传靶向。最后,其他研究将确定该治疗方案的潜力
与针对胶质母细胞瘤的常规疗法具有协同作用。总的来说,这些研究将调查新颖的
可直接翻译的肿瘤干细胞的肿瘤微环境的分子调节
进入临床试验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEREMY N RICH其他文献
JEREMY N RICH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEREMY N RICH', 18)}}的其他基金
Dynamic Complexity of Brain Tumor Stem Cells (R35CA197718)
脑肿瘤干细胞的动态复杂性 (R35CA197718)
- 批准号:
10419906 - 财政年份:2021
- 资助金额:
$ 34.23万 - 项目类别:
Dual Targeting of Brain Tumor Initiating Cells through Inhibition of BMI1 and EZH2
通过抑制 BMI1 和 EZH2 双重靶向脑肿瘤起始细胞
- 批准号:
9981829 - 财政年份:2017
- 资助金额:
$ 34.23万 - 项目类别:
Dual Targeting of Brain Tumor Initiating Cells through Inhibition of BMI1 and EZH2 (R01NS103434)
通过抑制 BMI1 和 EZH2 双重靶向脑肿瘤起始细胞 (R01NS103434)
- 批准号:
10450285 - 财政年份:2017
- 资助金额:
$ 34.23万 - 项目类别:
Dual Targeting of Brain Tumor Initiating Cells through Inhibition of BMI1 and EZH2
通过抑制 BMI1 和 EZH2 双重靶向脑肿瘤起始细胞
- 批准号:
9398480 - 财政年份:2017
- 资助金额:
$ 34.23万 - 项目类别:
Instructive Cues in Glioblastoma Hierarchies
胶质母细胞瘤层次结构中的指导性线索
- 批准号:
8786649 - 财政年份:2014
- 资助金额:
$ 34.23万 - 项目类别:
Energy Stress in Brain Tumor Initiating Stem Cells
脑肿瘤起始干细胞中的能量应激
- 批准号:
8785788 - 财政年份:2014
- 资助金额:
$ 34.23万 - 项目类别:
相似海外基金
Roles of immune cells derived from clonal hematopoiesis in B-cell lymphomas
克隆造血来源的免疫细胞在 B 细胞淋巴瘤中的作用
- 批准号:
24K19213 - 财政年份:2024
- 资助金额:
$ 34.23万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Identification of novel biomarkers for EBV-associated B-cell lymphomas arising in the oral cavity
口腔中出现的 EBV 相关 B 细胞淋巴瘤的新型生物标志物的鉴定
- 批准号:
23K15982 - 财政年份:2023
- 资助金额:
$ 34.23万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Chromunities Drive Transcriptional Reprogramming in Humoral Immunity and B-cell Lymphomas
染色体驱动体液免疫和 B 细胞淋巴瘤中的转录重编程
- 批准号:
10606730 - 财政年份:2023
- 资助金额:
$ 34.23万 - 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
- 批准号:
10566833 - 财政年份:2023
- 资助金额:
$ 34.23万 - 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
- 批准号:
10987699 - 财政年份:2023
- 资助金额:
$ 34.23万 - 项目类别:
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
HIV 感染者 EBV 阳性弥漫性大 B 细胞淋巴瘤的合成致死靶向
- 批准号:
10541285 - 财政年份:2022
- 资助金额:
$ 34.23万 - 项目类别:
Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas
Epstein-Barr病毒LMP2A蛋白在维持EBV B细胞淋巴瘤中致癌IgM信号传导中的作用
- 批准号:
10540952 - 财政年份:2022
- 资助金额:
$ 34.23万 - 项目类别:
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
HIV 感染者 EBV 阳性弥漫性大 B 细胞淋巴瘤的合成致死靶向
- 批准号:
10703446 - 财政年份:2022
- 资助金额:
$ 34.23万 - 项目类别:
Therapeutic potential of novel antibody-oligonucleotide conjugate for intractable B-cell lymphomas
新型抗体-寡核苷酸缀合物治疗难治性 B 细胞淋巴瘤的潜力
- 批准号:
22K08497 - 财政年份:2022
- 资助金额:
$ 34.23万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas
Epstein-Barr病毒LMP2A蛋白在维持EBV B细胞淋巴瘤中致癌IgM信号传导中的作用
- 批准号:
10707312 - 财政年份:2022
- 资助金额:
$ 34.23万 - 项目类别: